September 15, 2021

What Is the Role of Neoadjuvant Chemotherapy in Bladder Cancer With Variant Histology?

New findings could shape the treatment paradigm for a select group of bladder cancer patients

Plasmacytoid variant of urothelial carcinoma

Findings from a new Cleveland Clinic-led study help clarify the role of neoadjuvant chemotherapy in the management of bladder cancer with variant histology. Researchers presented these data at the 2021 American Urological Association meeting.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The prognosis for variant histology is generally worse than that of pure urothelial carcinoma. The treatment paradigm for the latter includes neoadjuvant chemotherapy with cisplatin followed by radical cystectomy. Treatment for non-muscle invasive bladder cancer with variant histology favors an aggressive therapeutic approach, progressing to radical cystectomy as a first-line therapy and bypassing neoadjuvant treatment altogether.

For patients with muscle-invasive bladder cancer with variant histology (with the exception of small cell carcinoma), the use of neoadjuvant treatment is unclear.

Rebecca Campbell, MD, a resident in Cleveland Clinic’s Glickman Urological & Kidney Institute and first author of the study, says this ambiguity led to a multi-institutional collaboration with colleagues at Mayo Clinic that helped jumpstart this investigation and others.

“These histologies are very rare and all previous literature comes from small single-institution series.”

Advertisement

Multi-institutional collaboration to address a gap in the literature

Together the teams partnered to create a larger database of patients with variant histology undergoing radical cystectomy than has previously been reported. They decided which histologies to include – urothelial, sarcomatoid, small cell carcinoma, nested, micropapillary and plasmacytoid – and determined pathologic downstaging after neoadjuvant chemotherapy would be a clinically meaningful endpoint.

“Downstaging occurred if the pathologic tumor stage at the time of radical cystectomy was lower than the clinical tumor stage, established at the time of transurethral resection of the bladder tumor,” she explains.

Their analysis included 889 patients, 303 with variant histology and 586 non-variant histology patients, all of whom underwent radical cystectomy from 1980 to 2018. Patients with variant histology were matched with pure urothelial carcinoma patients by age, sex, clinical tumor and nodal stages, year of radical cystectomy and receipt of the neoadjuvant chemotherapy.

“Our primary finding is that patients with variant histology can respond to neoadjuvant chemotherapy, demonstrated by pathologic downstaging,” Dr. Campbell says.

Advertisement

“Patients with pure urothelial carcinoma showed pathologic downstaging, which reinforces the role of neoadjuvant chemotherapy in their clinical management, and the matched variant histology cohort had strikingly similar rates.”

The rates of downstaging across variant histology subgroups varied, which should be considered, but Byron Lee, MD, PhD, senior author of the study and urologic oncologist in the Glickman Institute, says these findings provide a basis for broader inclusion of neoadjuvant therapy for this patient population going forward.

“This could mean potentially improving outcomes for select patients,” he says. “It answers some unknown questions in the management of these patients and opens the door for broader, multi-institutional collaborations to better understand this rare and comparatively aggressive pathology.”

Related Articles

Doctor measuring patient's waist size
February 26, 2024
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access

How antibody drug conjugates work
February 13, 2024
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

CQD-4445459-rotz-650×450
February 7, 2024
Advances in Bone Marrow Transplant Have Improved Outcomes in Fanconi Anemia

Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients

CQD-CHP4445461-hanna-sickle-650×450
February 5, 2024
Haploidentical Bone Marrow Transplant Has Durable Engraftment in Patients With Sickle Cell Disease

Two-year event-free survival comparable to matched sibling donor myeloablative transplant

24-CNR-4545611-CQD-Podcast-967×544
February 1, 2024
Possibilities of CRISPR Technology (Podcast)

Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors

CQD-CHP4445460-hanna-sickle-650×450
January 30, 2024
Gene Therapy Trials Show Positive Results in Sickle Cell Disease and Thalassemia

First-in-human trials of CRISPR-Cas12a gene editing demonstrate safety and meaningful event-free survival

photo of Elekta Esprit Gamma Knife machine
January 26, 2024
The Evolution of Gamma Knife Technology (Podcast)

Improvements enable targeting of brain tumors with single-session, fractionated or neoadjuvant approaches

Ad